Co-Authors
This is a "connection" page, showing publications co-authored by LUHUA WANG and VEERABHADRAN BALADANDAYUTHAPANI.
Connection Strength
0.171
-
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.
Score: 0.031
-
The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014 Jul 29; 111(3):628-36.
Score: 0.030
-
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92.
Score: 0.029
-
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014 Feb; 28(2):373-83.
Score: 0.028
-
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012 Oct 18; 120(16):3260-70.
Score: 0.027
-
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood. 2011 Oct 13; 118(15):4140-9.
Score: 0.025